Tests gene therapy GC101 in people with spinal muscular atrophy type 3
Tests gene therapy GC101, given into the spinal fluid, in people with SMA.
Plain-language title generated from the registry record
Registry title: Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1/2
Where in China
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- GeneCradle Inc
- Trial code
- NCT06421831
- Record updated
- 3 July 2025
- Original description
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.Read full original descriptionShow less
A Multi-center, Open Label, Single-arm, Dose Ascending Clinical Trial for Evaluation of Safety and Efficacy of Gene Therapy Drug GC101 in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients
The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 3 (SMA 3) patients.
Inclusion: ≥2 years of age on the day of signing the informed consent form; Genetic and clinical diagnosis of type 3 SMA with bi-allelic deletion of SMN1 of 5qSMA; Hammersmith Functional Motor Scale - Expanded (HFMSE) score is between 10 and 54 at screening; Female patients of childbearing age who are pregnant or lactating, as well as all enrolled patients （both male and female), should take effective contraceptive measures within 6 months after the treatment; Patients or patient's legal guardian(s) must be able to understand the purpose and risks of the study and voluntarily provide signed and dated informed consent prior to any study-related procedures being performed.
Exclusion: Patient who has participated in any previous gene therapy research trials; Patient who has AAV9 neutralizing antibody titer ≥1:200; Patient who has received Nusinersen within 120 days and Risdiplam within 15 days before treatment; Patient with previous injuries (such as upper or lower limb fractures) or surgical operations that have not fully recovered or reached a stable state; Vaccination no longer than 2 weeks before treatment; Patient who is positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis C antibody, or treponema pallidum antibody; Known allergy or hypersensitivity to prednisolone or other glucocorticosteroids or their excipients; Patient who has other serious diseases, such as severe cardiovascular and cerebrovascular diseases, digestive system diseases, urinary system diseases, endocrine system diseases, hematological diseases, immune system diseases, nervous system diseases (including but not limited to epilepsy, meningitis, history of convulsions or seizures, cerebrospinal fluid circulation disorders), and mental illnesses, etc; Patient who has any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the study; Patient who requires invasive or non-invasive ventilatory support averaging≥16 hours/day at screening; SMN2 copy numbers >4；; Patient who needs nasal or gastric tube feeding for eating; Severe contractures at screening that interfere with either the ability to attain/demonstrate functional measures or with the ability to receive intrathecal (IT) dosing.